Excellent news
This ASX announcement fromOncoSil Medical Limited (ASX: OSL)dated7 May 2025outlines a major comparative clinical study and its results, with key implications for both medical credibility and potential investor confidence. Here's what's happening:
1. Announcement of Clinical Study Results
OncoSil has released thefirst comparative analysisshowing itsOncoSil™ brachytherapy deviceisclinically superiortoStereotactic Body Radiation Therapy (SBRT)in treatinglocally advanced pancreatic cancer (LAPC) when used alongside chemotherapy.
Study Overview:
Study Type:Retrospective, investigator-initiated
Location:Royal Adelaide Hospital
Timeframe:March 2015 – August 2023
Sample Size:101 patients (42 OncoSil™, 59 SBRT)
Key Outcomes:
Overall Survival:22 months with OncoSil™ vs. 14 months with SBRT (HR: 1.98; p=0.004)
Progression-Free Survival:
Downstaging:24% (OncoSil™) vs. 4.7% (SBRT); p<0.001
Surgical Resection:22% (OncoSil™) vs. 0%; p<0.001
Adverse Events:Lower grade 3 AEs in OncoSil group; no grade 4 or 5 AEs in either group
These findings suggest that OncoSil™ not only improves survival rates but may also convert some previously inoperable cases into operable ones, which is a major advance in cancer treatment.
2. Scientific Recognition
Presented at:Digestive Disease Week (DDW2025)in San Diego, USA
Presenter:Dr Amanda Lim (RAH / Beth Israel Deaconess Medical Center)
This international presentation signals growing recognition of OncoSil’s device in leading medical circles.
3. Commercial Implications
OncoSil Medical is leveraging this new data toaccelerate commercialisationof its device.
Already hasCE MarkingandBreakthrough Device Designationin:
European Union
United Kingdom
United States
Approved in30+ countrieswith commercial activity already underway inSpain, Italy, and Israel.
This supports bothclinical adoptionandmarket expansion, which could havepositive financial implicationsfor the company.
4. Strategic Positioning
The study directly compares OncoSil™ withSBRT, which is considered the most precise external beam radiation therapy. Demonstratingsuperiority over SBRTpositions OncoSil™ as anew standardin treating LAPC, particularly for those unsuitable for surgery.
Conclusion
This announcement showcases asignificant validation milestonefor OncoSil Medical:
Clinically, by outperforming an industry gold standard (SBRT).
Commercially, by enabling broader uptake in global markets.
Financially, by improving its investment proposition with stronger efficacy data and international recognition.
(20min delay)